Professional Research
Frank I. Navetta, MD, FACC

Principal Investigator

• EPIC - A Phase III Study of Chimeric 7E3 Fab in Patients Undergoing High-risk Angioplasty
• Integrelin versus Aspirin in Unstable Angina - A Randomized, Double-blind, Comparative Safety and Efficacy Evaluation (Phase II) of Integrelin versus Aspirin in the Management of Unstable Angina
• IMPACT I - A Randomized, Double-blind Trial of Integrelin versus Placebo in the Setting of Coronary Angioplasty
• IMPACT II - A Randomized, Double-blind Efficacy and Safety Evaluation of Two Dosing Regimens of Integrelin versus Placebo for Reducing the Complication of Coronary Angioplasty
• The Use of Palmaz Biliary Stents in Large (>4.0mm Diameter) Saphenous Vein Grafts
• UTOPIA - Adjunctive Tissue Plasminogen Activator and Heparin During Angioplasty in UnstableAangina
• EPILOG - A Phase III, Randomized, Double-blind, Placebo-controlled Trial Evaluating 30 Day and 6 Month Clinical Outcome Following Percutaneous Coronary Intervention in Patients Treated with c7E3 Fab Bolus Plus 12 Hour Infusion Given with Either Standard-dose Weight-adjusted or Low-dose Weight-adjusted Heparin
• GUSTO III (Global Use of Strategies To Open Occluded Coronary Arteries) - A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction
• PURSUIT - A Randomized, Double-blind Evaluation of the Efficacy and Safety of Two Dosing Regimens of Integrelin versus Placebo for Reducing Mortality and Myocardial Re-infarction in Patients with Unstable Angina or Non Q-Wave Myocardial Infarction
• The Use of Phentermine and Fenfluramine in Obese Patients with Established Cardiovascular Disease
• TIMI 14 - A Phase II Randomized, Open-label, Angiographic Trial Evaluating the Benefit of ReoPro Bolus Plus 12 Hour Infusion Alone or in Conjunction with Thrombolytic Therapy for Acute Myocardial Infarction
• SADHART (Sertraline Antidepressant Heart Attack Randomized Trial) -A Randomized, Double-blind, Placebo-controlled Trial of Sertraline (Zoloft) for Major Depression After Acute Coronary Syndromes: Myocardial Infarction or Unstable Angina
• VAL-HeFT - A Multi-country, Randomized, Double-blind, Parallel, Placebo-Controlled Trial to Assess the Effect of Valsartan on Morbidity and Mortality, Signs and Symptoms, and Quality of Life in Patients with Stable, Chronic Congestive Heart Failure (NYHA Class II-IV)
• ATLAST - Antiplatelet Therapy versus Lovenox Plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosis
• SPEED (Strategies for Patency Enhancement in the Emergency Department) A Phase II, Randomized, Open-label, Angiographic Trial Evaluating the Benefit of ReoPro Bolus Plus 12 Hour Infusion With and Without Thrombolytic Therapy for Acute Myocardial Infarction
• PARAGON B - A Randomized, Double-blind, Placebo-controlled Study of Lamifiban (Ro 44-9883) in Patients with Unstable Angina/Non Q-wave Myocardial Infarction
• HALT MI - A Phase 2 Safety and Efficacy Study of Hu23F2G on Patients with Acute Myocardial Infarction with Direct Angioplasty
• INTRO AMI - A Pilot Phase II Safety and Efficacy Evaluation of Eptifibatide (Integrelin) in Patients Receiving Low Dose and Standard Dose Thrombolytic Therapy (Alteplase) for Acute Myocardial Infarction (AMI)
• GUSTO IV ACS - A Phase III, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of ReoProâ, Given as a Bolus Followed by a 24 or 48 Hour Infusion for the Treatment of Acute Coronary Syndrome Without ST Segment Elevation
• APLAUD - A 12 week, Double-blind, Parallel-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Platelet Aggregation of a Dose Range of SB 214857 When Added to Aspirin in Patients with Myocardial Infarction, Unstable Angina, Transient Ischemic Attack, or Stroke
• CAPRICORN - A Multi-national, Multi-center, Randomized, Double-blind, Parallel Group Study to Determine the Effects of Carvedilol on Mortality in Patients with Left Ventricular Dysfunction, With or Without Clinical Evidence of Heart Failure, Post Myocardial Infarction
• AMISTAD II - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor®, Adenosine Injection) as an Adjunct to Reperfusion Therapy (Thrombolysis or Mechanical Reperfusion) in the Treatment of Acute Anterolateral Myocardial Infarction
• WIZARD - A Randomized, Double-blind, Placebo-controlled Trial of the Effects of Weekly Azithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to C. Pneumoniae
• POSTIT - Boston Scientific Scimed, Inc.-Post Market Research Study on the NIR Stent and Other Commercially Available Coronary Stents
• BRACCO - A Clinical Evaluation to Determine the Optimal Imaging Parameters for Tc-99m Teboroxime in Subjects with Coronary Artery Disease and Subjects with No Evidence of Coronary Artery Disease
• RAFT - A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Slow Release Propafenone (Rythmol®-SR) in the Prevention of Symptomatic Recurrences of Atrial Fibrillation
• CREDO - A Double-blind, Randomized Trial of Clopidigrel 300 mg Loading Dose and Aspirin 325 mg Followed by Clopidigrel 75 mg and Aspirin Daily Compared with Placebo Loading Dose and Aspirin 325 mg Followed by Clopidigrel 75 mg and Aspirin Daily for the Prevention of Vascular Events and All-cause Mortality in Patients Undergoing Percutaneous Coronary Intervention
• CHARM (Candesartan Cilexetil in Heart Failure: Assessment of Reduction in Mortality and Morbidity) - Studies of Candesartan in Patients with Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function (0003), Who Are Treated With ACE Inhibitors and Have Depressed Left Ventricular Systolic Function (0006), and Patients with Heart Failure and Preserved Left Ventricular Function (0007) Sub-Investigator
• Phase I Study of a Monoclonal Antibody 7E3 F(ab')2 Against the Platelet Glycoprotein IIb/IIIa Receptor in Patients Undergoing Elective PTCA
• DUCCS 1 (Duke University Clinical Cardiology Study) - A Randomized Trial of Heparin in Conjunction with Anistreplase in Acute Myocardial Infarction
• DUCCS 2 (Duke University Clinical Cardiology Study 2) - A Randomized Trial of Anistreplase without Heparin versus tPA with Heparin in Acute Myocardial Infarction
• LATE (Late Assessment of Thrombolytic Efficacy) - An Anglo-Scandinavian North American Multi-center Trial of Alteplase Therapy in Patients who Present with Acute Myocardial Infarction Greater Than 12 Hours Following Onset of Symptoms
• TIMI 3 (Thrombolysis in Myocardial Ischemia and Unstable Angina) - The Comprehensive Management of Unstable Angina and Non Q-wave Infarction in a Randomized, Double-blind Fashion with tPA or Placebo
• Cardizem CD - The Safety and Efficacy of Cardizem-CD for the Treatment of Stable Angina Pectoris
• HIRULOG - A Comparative Study for the Safety and Efficacy of B68967 with Heparin in Patients with Unstable Angina Undergoing PTCA
• PRAISE (Prospective Randomized Amlodipine Survival Evaluation) - A Randomized, Double-blind, Dose-titration, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Amlodipine on Mortality and Morbidity in Patients with Severe Heart Failure
• CAVAEAT 2 - Coronary Angioplasty versus Excisional Atherectomy Trial in Saphenous Vein Grafts
• FIRST - A Multi-national, Open-label, Randomized, Parallel Group Comparison of the Effects of Chronic Flolan Therapy Plus Conventional Therapy to Conventional Therapy Alone on Survival in Patients with Severe Refractory Congestive Heart Failure
• CARS (Coumadin Aspirin Re-infarction Study) - A Randomized, Double-blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Reinfarction, Cardiovascular Death, and Stroke in Post-myocardial Infarction Patients
• TIMI 9 (Thrombolysis and Thrombin Inhibition in Acute Myocardial Infarction) - Hirudin in Acute Myocardial Infarction